Clinical safety and efficacy of the first-in-class Rho kinase inhibitor for lowering IOP: netarsudil and the fixed-dose combination of netarsudil and latanoprost €15.00 Clinical safety and efficacy of the first-in-class Rho kinase inhibitor for lowering IOP: netarsudil and the fixed-dose combination of netarsudil and latanoprost quantity Add to cart Category: Articles Tag: Volume 3 Description Description Authors: Janet B. Serle, Jake Radell Related products Biomarkers in primary open-angle glaucoma €15.00 Add to cart Novel surgical methods for addressing glaucoma €15.00 Add to cart Molecular differences in segmental regions of the trabecular meshwork €15.00 Add to cart Autophagy in outflow pathway physiology and pathophysiology €15.00 Add to cart